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Evaluation of a Bioactive Glass
Alloplast in Treating Periodontal
Intrabony Defects
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This study evaluated the use of bioactive glass (BG) for repairing/regenerating
periodontal intrabony defects. Fourteen systemically healthy patients participated. Each
patient had 2 contralateral sites with > 6 mm clinical probing depth and radiographie
evidence of an intrabony defect. One defect was treated with flap debridement plus
BG (test) and the other with flap debridement alone (control). Baseline measurements
included gingival index (GI), plaque index (PI), position of the free gingival margin
(S/FGM), clinical attachment level (CAL), probing depth (PD), and mobility. At the
time of surgery and at surgical reentry (9 to 13 months later), hard tissue measurements
included: stent to defect base, bone crest to defect base, and defect width at the bone
crest. One-way repeated ANOVA was used to analyze the treatment effect. Friedman's
test was used to detect any significant changes of GI, PI and mobility at different time
periods (baseline, 3 months, 6 months, and reentry). For multivariate analysis, the
random coefficients mixed effect model was applied to adjust the intra-correlation
effect. Both treatments resulted in decreased PD and gain of CAL. These changes
were only significant (P < 0.05) for the BG treated sites (PD reduction = 1.24 ±
0.43 mm, CAL gain = 0.87 ± 0.38 mm) from baseline. Defect fill was significant for
test (1.1 ± 0.4 mm) and control (1.4 ± 0.4 mm) alike (P < 0.01). Although BG
treated sites had more PD reduction and CAL gain than debridement only controls,
there were no statistically significant differences between groups for any parameter
measured. Further studies are required to clarify the beneficial effects, if any, of BG
alloplast in treating periodontal intrabony defects. / Periodontol 1998;69:1346-1354.
Key Words: Grafts/bone; periodontal diseases/therapy; glass, biologically active; peri-
odontal regeneration; surgical flaps.
Many bone grafting materials have been developed and
tested for use in periodontal regeneration. Autografts, al-
lografts, and alloplasts are the major types of commonly
used bone graft materials.1 Of the currently available bone
graft materials, only autogenous bone grafts (autografts)
are truly osteogenic. Autografts of cancellous bone may
contain viable cells that can form new bone when im-
planted in a periodontal intrabony defect.23 Autografts,
 Currently, National Dental Centre Pte. Ltd., Singapore; previously, De-
partment of Periodontics/Prevention/Geriatrics, School of Dentistry, Uni-
versity of Michigan, Ann Arbor, MI.
department of Periodontics/Prevention/Geriatrics.
*Currently, University of Connecticut; previously, Department of Peri-
odontics/Prevention/Geriatrics.
department of Cariology, Restorative Sciences, and Endodontics.
"Division of Biostatistics, Department of Preventive Medicine, School of
Medicine, Vanderbilt University, Nashville, TN.
however, are often impractical because a second surgical
site is often needed and available quantities are limited.
Allografts, such as demineralized freeze-dried bone
(DFDBA), have been an effective alternative to autoge-
nous grafts.4-5 DFDBA contains no viable bone cells;
therefore, it is not osteogenic. DFDBA contains bone
morphogenic proteins (BMPs) that can, when implanted
in a periodontal defect, induce the surrounding tissues to
produce bone.6 Therefore, DFDBA is osteoinductive.
DFDBA is widely used and has an exceptional safety rec-
ord.7 Some patients, however, still choose not to have im-
plants of DFDBA because it is procured from cadavers.
Additionally, the osteoinductive properties of DFDBA
can vary depending on the procurement and preparation
procedures followed.8 Therefore, the quality of DFDBA
may vary from bone bank to bone bank.
Alloplasts, or synthetic bone graft materials, can be
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made in unlimited quantities. This a distinct advantage
over autografts and allografts.9 Unfortunately, alloplasts
available until recently (e.g., hydroxyapatite and trical-
cium phosphate) have yielded inconsistent clinical results
and disappointing histological results, often evidenced by
fibrous encapsulation of the graft particles.10-24 Alloplasts
are osteoconductive; i.e., they act as a scaffold to support
new bone growth but they neither generate new bone nor
induce new bone formation.
Recent studies report that a newer ceramic alloplast,
bioactive glass (BG), in addition to being osteoconduc-
tive, bonds directly to bone tissue.25-26 In the presence of
body fluids, through a series of ion exchange reactions,
BG forms a surface layer consisting of two parts: an inner
silica (Si ) -rich layer and an outer calcium-phosphate
(CaP) -rich layer. This CaP-rich layer is believed to en-
courage osteoblasts to deposit organic bone matrix.25-27
Ionic sites on collagen and mucopolysaccharides of the
organic bone matrix cross-link with sites on the CaP-rich
layer. This cross-linking achieves a bond between BG and
the surrounding bone.28 BG has been used to maintain
alveolar ridges29-32 and to repair periodontal defects and
bony lesions.33-37
Wilson and Law treated surgically created periodontal
defects in monkeys with bioactive ceramic materials: tri-
calcium phosphate (TCP); hydroxyapatite (HA); and two
compositions of BG (45% Si02, 24.5% CaO, 24.5%
Na20, 6% P205and 43% Si02, 14% CaO, 13% CaF2, 24%
Na20, 6% P205).34 After 9 months, both compositions of
 G promoted bone regeneration and inhibited epithelial
downgrowth. In contrast, TCP and HA treated sites healed
with a long junctional epithelial attachment that was sim-
ilar to the unfilled control defects.34
Schepers et al. treated 106 bone defects in 87 patients
with BG implants.36 The BG had a narrow particle size
range of 300 to 360 pm. The bone defects included apical
resection areas, cystic lesions, extraction sockets, and al-
veolar ridge deficiencies. They reported that at 3 months,
 G became fully solidified clinically and radiographically
appeared to be integrated with bone tissue.
Schepers and Pinruethai also treated surgically created,
ligature-induced periodontal defects in beagle dogs with
either BG (particle size 300 to 360 pm) or porous HA.38
Both treatments resulted in reduced PD and gain of CAL.
BG treated sites, however, showed a better gain of CAL
(1 mm) when compared to HA treated sites (0.25 mm).
Histologically, bone formed around the BG particles re-
gardless of their location; however, bone only formed
around HA particles that were close to the preexisting
bone.38
More recently, Zamet et al. in a controlled clinical trial
of 20 patients with 44 intrabony defects, reported that
intrabony periodontal pockets treated with BG had sig-
nificantly better radiographie density and volume than de-
bridement only control sites.39 They also reported that
there was a trend towards more PD reduction and CAL
gain in the  G treated sites; however, the differences were
not statistically significant.
Thus, studies indicate that BG shows promise for use
in periodontal repair/regeneration. To date, there have
been limited studies evaluating BG for use in the treat-
ment of periodontal intrabony in humans.39 The results of
these studies were inconclusive. Therefore, the purpose of
this study was to evaluate bioactive glass as an alloplastic




Fourteen systemically healthy patients, 11 males and 3
females, ages 35 to 67 years (mean = 49.1 years), par-
ticipated in this study. All were patients of the Depart-
ment of Graduate Periodontics at The University of Mich-
igan, School of Dentistry. The Human Subject Review
Committee of The University of Michigan approved the
study protocol. Patients were enrolled in the study if they
met the following criteria: 1) hygiene phase therapy had
been completed (oral hygiene instruction, scaling and root
planing, and possibly occlusal therapy) or the patient had
received hygiene phase therapy in the past and was now
in a periodontal maintenance program; 2) evidence of lo-
calized moderate to severe Periodontitis; 3) two contra-
lateral periodontal intrabony defects with probing depths
a 6 mm; 4) radiographie evidence of an intrabony defect
that measured at least 3 mm from the alveolar crest to the
base of defect; 5) no antibiotic therapy in the past 6
months; 6) no periodontal surgery in the areas to be treat-
ed within the last 12 months; and 7) no known allergy to
materials and drugs used or prescribed in this study, in-
cluding silica products. All patients gave informed con-
sent prior to entering the study.
Measurements
The following were recorded at baseline (time of sur-
gery), at 3 months, at 6 months, and at 9 to 13 months
after surgery: PD; CAL; position of the free gingival mar-
gin (S/FGM); mobility;40 gingival index (GI);41 and
plaque index (PI).42 PD and CAL were measured with an
automated probe11 set to a standardized force of 20 grams
(Fig. 1). S/FGM was measured with a North Carolina 15
mm probe from a reference notch on a vacuum formed
acrylic stent to the free gingival margin of the defect site.
The stent also served as a reference for measuring CAL
(Fig. 1). Vertical grooves in the stent aided in aligning
the probe. A horizontal groove in the stent created a ledge
that served as a reference point for taking measurements.
The stent was not used to measure PD. PD measurements
'Florida Probe Co., Gainesville, FL.
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Figure 1. Demonstrates how clinical measurement, CAL, was taken from
the surgical Stent ledge and grooves.
were made from the gingival margin to the base of the
sulcus/pocket. For interproximal PD and CAL measure-
ments, the examiner angled the probe to measure the
depth of the defect at the midpoint of the tooth facio-
lingually. Interproximal PD and CAL measurements were
taken from the buccal and lingual aspects and then av-
eraged to better represent the site. At 1, 2, and 4 weeks
after surgery, only GI and PI were recorded.
Hard tissue measurements were recorded at the time of
surgery and at the 9- to 13-month reentry surgery. The
measurements were taken after the defects had been de-
brided of all granulation tissue. Hard tissue measurements
included: stent to base of defect (SB), crest of bone to
base of defect (CB), buceo-lingual (B-L) defect width at
the alveolar crest, and mesio-distal (M-D) defect width at
the alveolar crest. Stent to crest of bone (SAC) was cal-
culated by subtracting CB from SB (Fig. 2). The auto-
mated probe with a standardized force of 20 grams was
used to measure stent to base of bone defect (SB) (Fig.l).
The North Carolina probe was used to record alveolar
crest to the base of defect (deepest portion) using a groove
on the stent as a reference point for site identification; B-
L horizontal defect width at the alveolar crest; and M-D
horizontal defect width at the alveolar crest. Single site
values were used for analyzing all hard tissue measure-
ments.
Film holders with custom acrylic bite registration in-
dices were used to take standardized periapical radio-
graphs at baseline (prior to surgery), 6 months after sur-
gery, and 9 to 13 months after surgery.44
One examiner (MIK) was calibrated prior to the study
and made all measurements during the course of the
study. The examiner was masked to the procedures per-
formed.
Surgical Protocol
All surgical procedures were carried out from January
1996 to September 1996 in the Department of Graduate
Figure 2. Hard tissue measurement method.
Initial measurements:
SB = Stent to base of defect









Stent to alveolar crest at reentry
Defect fill = SB
-
SB'
Base of initial defect to base of reentry defect
Crestal résorption = SAC
-
SAC
Reentry alveolar crest to initial alveolar crest
Reentry measurements (not pictured):
SB' = Alveolar crest to base of defect
CB1 = Alveolar crest to base of defect
Periodontics surgical clinic at The University of Michigan
School of Dentistry. Graduate periodontic residents, in-
cluding the primary investigator (MO), performed the
surgeries. The primary investigator designed and per-
formed all initial flap incisions. The primary investigator
also supervised the debridement of defects, fill of test
sites with  G and placement of sutures to ensure that each
surgeon adhered to the study protocol. All surgeries were
photodocumented by the primary investigator (MO).
Apart from graft placement, surgical procedures were
identical for test and control sites. Following adequate
local anesthesia, buccal and lingual intrasulcular incisions
were made and full thickness flaps were elevated with
care to preserve the interdental papillae. After debride-
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ment of the osseous defects, the root surfaces were scaled
and root planed with ultrasonic and hand instruments to
a smooth, hard consistency. When bleeding was not ob-
served in the defect area, intramarrow penetration through
the defect walls was performed with a 1/2 round bur.
At the time of surgery, patients were randomly as-
signed to receive test or control treatments on the right
or left side by drawing a coded paper from a paper bag.
This was done to avoid operating bias (right versus left
side). Surgeons filled the intrabony defects at the test sites
to the level of the alveolar crest with  G (90 to 710 µ  
particles)** that had been wetted with sterile water ac-
cording to the manufacturer's directions. The control sites
received no bone graft but were otherwise treated iden-
tically. Silk horizontal mattress sutures were used to close
the defect sites. The remaining flap was sutured with in-
terrupted 4-0 black silk sutures.
Patients received routine written and oral postoperative
instructions. All patients were instructed to rinse with 1/
2 ounce 0.12% Chlorhexidine gluconate twice daily for a
period of 2 weeks. After 2 weeks, patients used a cotton
tip applicator to apply the Chlorhexidine directly to the
surgery sites twice daily. Patients resumed normal brush-
ing and flossing 6 weeks after surgery. At that time they
discontinued Chlorhexidine use. No antibiotics were pre-
scribed unless postoperative complications developed.
The sutures were removed after 1 week. After surgery,
patients were seen at 2 weeks, 4 weeks, 3 months, 6
months, and 9 to 13 months for tissue evaluation, plaque
debridement, and oral hygiene review.
Nine to 13 Months Reentry Surgery
Reentry surgeries were performed 9 to 13 months after
the initial surgery. Clinical measurements (Gl, PI, PD,
CAL, S/FGM, mobility) were recorded prior to reentry.
After making sulcular incisions, full-thickness mucoperi-
osteal flaps were elevated to expose the previously treated
test and control sites. Defect sites were debrided of all
granulation tissue until firm, hard bone was reached. Clin-
ical photographs and hard tissue measurements were tak-
en as previously described. Osteoplasty was performed as
needed to correct any residual osseous defects. Flaps were
then replaced and sutured. Patients returned at 1 week for
suture removal. All patients were placed on 3-month re-
call for supportive periodontal treatment.
Statistical Analysis
A statistical software program*1 was used for all data anal-
ysis. The data were organized and presented as means ±
standard error. Prior to the initiation of this study, a power
calculation was done to determine the sample size re-
quired. The estimated standard deviation of the measure-
**PerioGlas, USBiomaterials Corp., Alachua, FL.
"Version 6.12, SAS Institute, Gary, IN.
ment parameter was set at 0.7 mm The minimum detect-
ing difference between pre- and post-treatment status was
set at 1.0 mm44 With  set at 0.05 and the power of the
study set at 95%, a minimum number of 9 patients was
required to allow a 95% chance of detecting a statistically
significant difference. Analysis of the treatment effect at
each time point (baseline, 3 months, 6 months, and 9 to
13 months reentry) was completed using the one-way re-
peated measures ANOVA for the normally distributed
continuous parameters; e.g., attachment level, and Fried-
man's test for the non-normally distributed continuous pa-
rameters; e.g., mobility. Similar statistical methods were
used for testing the hypothesis concerning time effect for
each treatment group. The multivariate analysis was ap-
plied using the restricted/residual maximum likelihood
(REML)-based random coefficient mixed effect model to
adjust for the intra-correlation effect, treatment effect,
time effect and the interaction effect between treatment
and time. All tests of significance were 2-sided, and dif-
ferences were considered statistically significant when  
< 0.05.
Examiner Calibration
A patient with 2 contralateral intrabony defects and prob-
ing depths ^ 6 mm with attachment loss was used to
calibrate the examiner (MIK). The examiner evaluated the
patient on 2 separate occasions, 10 days apart. Two sets
of measurements were made at each visit, with a 45 mi-
nute lag-time between measurements. Probing depth and
clinical attachment level were measured at 6 sites around
each of 2 teeth. The automated probe was used to make
the measurements and an acrylic stent was used as a ref-
erence for measurements. The intraexaminer correlation
coefficient of the single calibrated examiner was 0.94 us-
ing the Pearson (parametric) correlation test.
RESULTS
Fourteen patients participated in this study. Of the 28
teeth selected, one site did not qualify at the time of sur-
gery because a root fracture was noted on the involved
tooth. Therefore, 14 teeth were treated as controls (flap
debridement) and 13 teeth were treated as test sites (flap
debridement plus BG). Reentry surgery was performed
between 9 to 13 months from baseline. Patient demo-
graphic information is shown in Table 1.
Few postoperative complications were noted. Two of
the  G treated sites initially developed a pebbled surface
texture interproximally but this eventually disappeared.
One control site developed an abscess at 1 week postsur-
gery. The patient was treated with amoxicillin 500 mg
t.i.d. for 7 days. The site healed without further compli-
cations.
There were no significant differences between the test
and control groups at any time period for GI, PI, and
mobility (Table 2).
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Table 1. Patient Information
Patient Gender Age
Debridement Debridement + Reentry





















































































Table 2. Comparison of Clinical Parameters Between Control (flap
debridement,  = 14) and Test (flap debridement + BG,  = 13)
(reported as mean ± standard error)
Parameters/












0.6 ± 0.2 0.5 ± 0.2







































Table 3 lists the soft and hard tissue measurements at
baseline and reentry. There were no statistically signifi-
cant differences between test and control groups for any
of the parameters measured at baseline or reentry.
With regard to soft tissue measurements, BG treated
sites had significant changes in PD, CAL, and S/FGM
when compared to baseline (P < 0.05, Table 3). Table 4
shows these changes to be 1.24 ± 0.43 mm PD reduction,
0.87 ± 0.38 mm CAL gain, and 0.7 ± 0.3 mm recession.
The control group also experienced reduced PD, gain of
CAL, and increased recession (S/FGM); however, the
changes were not statistically significant (Table 3). The
changes in PD, CAL, and S/FGM for the test group tend-
ed to be greater than for the controls, but the differences
between groups were not significant (Table 4).
There were no significant differences between test and
control groups for baseline and reentry hard tissue mea-
surements (SB, CB, B-L defect width, and M-D defect
width) (Table 3). The arithmetic determinations of vertical
defect fill and eresiai bone change are illustrated in Figure
2. Vertical defect fill was statistically significant (P <
0.01) for control (1.4 ± 0.4 mm) and test groups (1.1 ±
0.4 mm ) (Table 4). Even though there tended to be more
defect fill for the controls than the test group, the differ-
ence between the groups was not statistically significant.
The difference between baseline and reentry values for
SAC represent the amount of crestal résorption that oc-
curred (Fig. 2). The test group exhibited 0.5 mm of mean
crestal bone résorption while the control group exhibited
0.1 mm of mean crestal bone deposition. The difference
between the groups was not statistically significant (Table
4).
Both groups had improvements in B-L defect width
(test = 1.8 ± 0.5 mm, control = 0.6 ± 0.6 mm) and M-
D defect width (test = 1.6 ± 0.6 mm, control = 0.5 ±
0.3 mm). These changes were only significant for the test
group (P < 0.05, Table 3). However, there was no sig-
nificant difference between the test and control groups
(Table 4).
There were no statistically significant differences noted
between test and control groups for any parameter mea-
sured at baseline or reentry (Table 3). Furthermore, there
were no significant differences between groups with re-
gard to changes (improved, unchanged, or worsened) in
clinical measurements from baseline to reentry (Table 4).
Table 5 shows the defect morphology in relation to the
number of sites with >50% or <50% defect fill. Control
sites had >50% defect fill 36% of the time and test sites
Table 3. Clinical Measurements (mm) for Control (flap debridement,  = 14) and Test (flap debride-
ment + BG,  = 13) at Baseline and Reentry (reported as mean ± standard error)
Control Test










































 Statistically significant difference (P < 0.05) from baseline. PD = probing depth. CAL = Clinical attach-
ment level. S/FGM = stent to free gingival margin. SB = stent to base of defect. B-L = bucco-lingual
width. M-D = mesio-distal width. SAC = stent to alveolar crest (calculated).
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Table 4. Clinical Changes (mm) for Control (flap debridement,  = 14) and Test (flap debridement
+ BG,  = 13) Reentry (reported as mean ± standard error)
Measurement Control Test Difference
Soft tissue
PD reduction 0.68 ± 0.35 1.24 ± 0.43 -0.59 ± 0.53
CAL gain 0.48 ± 0.42 0.87 ± 0.38 -0.36 ± 0.41
Increase gingival recession
(S/FGM change) 0.4 ± 0.3 0.7 ± 0.3 -0.3 ± 0.3
Hard tissue
Vertical defect fill 1.4 ± 0.4 1.1 ± 0.4 0.4 ± 0.6
B-L defect fill 0.6 ± 0.6 1.8 ± 0.5 -1.2 ± 0.7
M-D defect fill 0.5 ± 0.3 1.6 ± 0.6 -1.2 ± 0.5
Crestal résorption -0.1 ± 0.6 0.5 ± 0.4 -0.6 ± 0.7
No statistically significant differences were found between the treatment groups.
Table 5. Defect Morphology in Relation to Percentage of Defect
Fill of Control (flap debridement,  = 14) and Test (flap debride-
ment + BG,  = 13) Sites
Control Test
Defect Defect Fill Defect Fill Defect Fill Defect Fill
Morphology >50% <50% >50% <50%
1 wall 110 0
2 wall 2 3 2 4
3 wall 0 0 11
1-2 wall 12 0 2
2-3 wall 13 0 3
Total 5 9 3 10
% 35.7 64.3 23.1 76.9
had >50% defect fill 23% of the time. Control sites had
mean bone fill of 36.4% and test sites had mean bone fill
of 27.9%. There was no significant difference in the per-
centage bone fill between groups.
DISCUSSION
In this study, BG caused no adverse clinical side effects.
Two test sites developed a pebbled surface texture during
the first weeks after surgery. This eventually resolved to
a normal surface texture. All other test sites healed un-
eventfully. One of the control sites developed an abscess
at 1 week but it resolved with antibiotic treatment. The
postoperative infection incidence was 0.07% (1 out of 14)
for the control sites and 0% for the test sites. This com-
pares favorably with Pack and Haber, who reported an
infection rate of <1.00% after periodontal surgery when
no adjunctive antibiotics were prescribed.45
GI and PI scores for both our treatment groups were
low (Table 2). There was little inflammation at the bio-
active glass treated sites. In addition, no infections de-
veloped at the BG treated sites. This agrees with other
reports that indicate  G is biocompatible at the clinical
and histologie level.3334 35 39
Treatment of intrabony defects with  G or debridement
resulted in PD reduction (test = 1.24 mm, control = 0.68
mm), gain of CAL (test = 0.87 mm, control = 0.48 mm)
and increased recession (test = 0.7 mm, control = 0.4
mm). These changes were greater for  G treated sites
than debridement treated sites; however, the differences
did not reach a level of statistical significance (Table 4).
Our findings agree with the clinical findings reported by
Zamet et al.39 In addition, they used computer aided den-
sitometric image analysis (CADIA) and found signifi-
cantly better bone density and volume (P < 0.001) in BG
treated sites. This, however, could be attributed to unre-
sorbed, non-incorporated BG particles in the defects. In
the present study, granulation tissue containing BG par-
ticles often was curetted from defects at reentry.
PD reduction, CAL gain, recession, M-D defect fill, B-
L defect fill, and vertical defect fill were statistically sig-
nificant for the BG treated sites in this study (P < 0.05).
For the control sites, however, only vertical defect fill was
significant (P < 0.05). Studies that evaluated other allo-
plastic materials have reported greater PD reduction
(mean range 2.5 to 4.3 mm) and CAL gain (mean range
of 1.0 to 3.6 mm) than we report here.17-46-50 The debride-
ment-only groups in those studies yielded less PD reduc-
tion (2.3 to 3.4 mm) and CAL gain (0.7 to 1.2 mm) than
the alloplast treated test sites. In this study, gingival re-
cession averaged 0.7 mm for the test teeth and 0.4 mm
for the control teeth. This is less recession than others
reported for comparable alloplasts (grafted sites, 1.2 to
1.6 mm versus non-grafted sites —1.1 to 2.0 mm).'7-4648
Differences in measuring techniques may account for
some of the variance in results. Many of the previous
studies used conventional periodontal probes while we
used an electronic probe.1617·46-47·49 51 Badersten et al. re-
ported that using an electronic probe in conjunction with
a stent decreases measurement error and reduces the var-
iance of measuring CAL.52 On the contrary, a recent study
reported that intra- and inter-examiner reliability was bet-
ter with manual probes than electronic probes.53 The main
advantages of the electronic probe are that measurements
can be made to the nearest 0.1 mm and the data are input
directly to a computer.53
We made hard tissue measurements after flaps were
elevated and defects were thoroughly debrided. Some of
the graft material appeared to be firmly embedded within
the granulation tissue. Most of this granulation tissue was
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removed with a curet until a firm bony base was reached.
Some regenerated tissue may have been removed in the
process. This may explain why debridement treated sites
had greater defect fill than  G treated sites (1.4 mm ver-
sus 1.1 mm). The amount of vertical bone fill in each
group was significant ( ^ 0.01); however, the difference
between groups was not statistically significant. Nine
months may be too early to expect complete bone re-
modeling after bone grafting with BG. Zamet et al. found
that even at 12 months there was a significant difference
in the density of BG grafts and the surrounding bone.39
They suggested that bone remodeling may have been in-
complete at that time. It is possible that we would have
gained more defect fill if we had waited longer.
The mean percentage defect fill in this study was 36.4%
for control sites and 27.9% for test sites. The difference
between the groups was not statistically significant. In this
study, 35.7% of control sites had >50% defect fill while
23.1% of test sites had >50% defect fill (Table 5). Fur-
thermore, of the test teeth that initially had 2/3- or 3-wall-
defects, only 20% (1/5) had >50% fill. In comparison,
Sepe et al. reported that 63% of intrabony defects treated
with DFDBA exhibited >50% fill.4 Other studies that
evaluated alloplastic grafting materials reported defect fill
ranging from 47% to 67%.17-23-47-49-50
Defects in this study tended to be wider and not as
deep as those reported in other studies.17-23 The average
M-D defect width was 3.2 ± 0.3 mm for controls and 3.9
± 0.7 mm for test sites. The average initial defect depth
was 4.5 ± 0.4 mm for control and 4.2 ± 0.3 mm the test
sites. Thus, test sites were initially shallower and wider
than the control sites. The initial differences in M-D de-
fect width and defect depth, however, were not significant.
Also, 71 % (10/14) of the control and 63 % (8/13) of the
test sites were 1-wall, 1/2-wall combination or 2-wall de-
fects. It is well known that less fill can be expected in
defects with fewer remaining walls.2 As pointed out ear-
lier, however, only 20% of the 3-wall and 2/3-wall com-
bination defects that we grafted with BG achieved >50%
fill.
Finally, we used BG with a wide particle size range of
90 to 710 pm. Other studies that used alloplasts with
narrower size ranges (425 to 625 pm;16 380 to 520 pm47
and 340 to 540 pm54) reported better mean defect fill and
percentage defect fill in grafted versus non-grafted control
sites. Schepers and Ducheyne found histologie evidence
of enhanced bone repair when they used a narrow size
range (300 to 355 pm) of BG particles.55 They suggested
cells can migrate into spaces between uniformly sized
graft particles to form new bone. In contrast, when a wide
size range (100 to 710 pm) of particles was used, smaller
graft particles filled the spaces between the larger ones.
As a result, infiltration of the BG implant with new bone
was hindered.55 Furthermore, Furusawa and Mizunuma,
demonstrated bone growth in sinuses augmented with a
narrow size range of BG particles (300 to 355 pm).56 On
the contrary, Fucini et al.,57 treated human intrabony peri-
odontal defects with small (250 to 500 pm) and large
(850 to 1000 pm) particles of DFDBA. They found no
statistically significant difference in the amount of mean
defect fill between the two particle size ranges.
Control sites gained crestal bone (—0.1 mm CR) while
test sites lost crestal bone (0.5 mm CR) during this study
(Table 4). These differences were not statistically signif-
icant. Other studies have reported more mean CR in non-
grafted control groups (0.18 to 1.3 mm) and less CR with
grafted test groups (-0.61 to 0.60 mm).17-2346"50 Wood et
al.58 and Poison and Heijl59 reported crestal résorption af-
ter full thickness flap surgery similar to what we report
here for BG treated sites.
We found flap debridement, with the addition of intra-
marrow penetration, resulted in significant vertical bone
fill. This corroborates similar positive results others have
reported after flap debridement surgery.59 61 Others, how-
ever, have reported minimal bone defect response after
open flap debridement.17 23 5162 63 Significant differences in
the defect selection criteria, methods of measurement,
data analyses, and decisions to use reentry evaluation may
account for some of the differences observed between
these studies.
An interesting finding of this study was that soft tissue
changes were not of the same magnitude as hard tissue
changes. One would expect that the magnitude of change
for CAL and defect fill would be similar but we found
greater defect fill than CAL gain (Table 4). This was true
for test and control groups. Rabalais et al. reported similar
results.49 They suggested two reasons for the observed
discrepancy. First, there may be variations in probe pen-
etration through the soft tissues because of variations in
probing force and tissue tone.64 Second, during the reentry
surgeries all of the soft tissues are removed from the in-
trabony defects prior to making measurements. Because
of this discrepancy between soft and hard tissue mea-
surements, we feel that it is necessary to perform reentry
surgeries or bone sounding to accurately assess regener-
ative treatment outcomes.
Limitations of this study include short duration, small
sample size, and restrictions in defect selection. If the
study had been longer, better results may have been ob-
tained at the grafted sites. With a larger sample size, some
of the differences between the groups may have reached
a level of significance. In addition, the grafted sites may
have had more dramatic changes had the initial defects
been deeper and had at least 2 remaining walls. Hence,
further studies of longer duration, with larger sample siz-
es, and more controlled defect selection are needed.
From this study, the following conclusions can be
drawn: 1) Flap debridement and flap debridement plus
 G both resulted in decreased PD and gain of CAL.
These changes were only significant for the BG treated
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group ( < 0.05). 2) Both treatments resulted in signifi-
cant vertical defect fill (P < 0.01). 3) Results at sites
treated with BG did not differ significantly from sites
treated with debridement alone. 4) Bioactive glass was
well tolerated by human tissues. 5) Further studies are
required to clarify the beneficial effects, if any, of bio-
active glass in treating periodontal intrabony defects.
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